Citation: | Weilun Cheng, Wanqi Mi, Shiyuan Wang, Xinran Wang, Hui Jiang, Jing Chen, Kaiyue Yang, Wenqi Jiang, Jun Ye, Baoliang Guo, Yunpeng Zhang. Dissection of triple-negative breast cancer microenvironment and identification of potential therapeutic drugs using single-cell RNA sequencing analysis[J]. Journal of Pharmaceutical Analysis. doi: 10.1016/j.jpha.2024.100975 |
[1] |
. H. Sung, J. Ferlay, R.L. Siegel, et al., Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J. Clin. 71 (2021) 209-249.
|
[2] |
. C.M. Perou, T. Sørlie, M.B. Eisen, et al., Molecular portraits of human breast tumours, Nature 406 (2000) 747-752.
|
[3] |
. A. Goldhirsch, W.C. Wood, A.S. Coates, et al., Strategies for subtypes-Dealing with the diversity of breast cancer:Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011, Ann. Oncol. 22 (2011) 1736-1747.
|
[4] |
. F.M. Howard, O.I. Olopade, Epidemiology of triple-negative breast cancer, Cancer J. 27 (2021) 8-16.
|
[5] |
. N. Harbeck, M. Gnant, Breast cancer, Lancet 389 (2017) 1134-1150.
|
[6] |
. W.J. Gradishar, M.S. Moran, J. Abraham, et al., NCCN guidelines® insights:Breast cancer, version 4.2023, J. Natl. Compr. Canc. Netw. 21 (2023) 594-608.
|
[7] |
. Y. Li, H. Zhang, Y. Merkher, et al., Recent advances in therapeutic strategies for triple-negative breast cancer, J. Hematol. Oncol. 15 (2022), 121.
|
[8] |
. S. Ding, X. Chen, K. Shen, Single-cell RNA sequencing in breast cancer:Understanding tumor heterogeneity and paving roads to individualized therapy, Cancer Commun. Lond. Engl. 40 (2020) 329-344.
|
[9] |
. R. Sklavenitis-Pistofidis, G. Getz, I. Ghobrial, Single-cell RNA sequencing:One step closer to the clinic, Nat. Med. 27 (2021) 375-376.
|
[10] |
. Y. Zhang, H. Chen, H. Mo, et al., Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer, Cancer Cell 39 (2022) 1578-1593.
|
[11] |
. T. Liu, C. Liu, M. Yan, et al., Single cell profiling of primary and paired metastatic lymph node tumors in breast cancer patients, Nat. Commun. 13 (2022), 6823.
|
[12] |
. M. Karaayvaz, S. Cristea, S.M. Gillespie, et al., Unravelling subclonal heterogeneity and aggressive disease states in TNBC through single-cell RNA-seq, Nat. Commun. 9 (2018), 3588.
|
[13] |
. A. Sebastian, N.R. Hum, K.A. Martin, et al., Single-cell transcriptomic analysis of tumor-derived fibroblasts and normal tissue-resident fibroblasts reveals fibroblast heterogeneity in breast cancer, Cancers 12 (2020), 1307.
|
[14] |
. C. Curtis, M. Group, S.P. Shah, et al., The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups, Nature 486 (2012) 346-352.
|
[15] |
. E. Cerami, J. Gao, U. Dogrusoz, et al., The cBio cancer genomics portal:An open platform for exploring multidimensional cancer genomics data, Cancer Discov. 2 (2012), 960.
|
[16] |
. Y. Hao, T. Stuart, M.H. Kowalski, et al., Dictionary learning for integrative, multimodal and scalable single-cell analysis, Nat. Biotechnol. 42 (2024) 293-304.
|
[17] |
. I. Korsunsky, N. Millard, J. Fan, et al., Fast, sensitive and accurate integration of single-cell data with Harmony, Nat. Meth. 16 (2019) 1289-1296.
|
[18] |
. A. Subramanian, P. Tamayo, V.K. Mootha, et al., Gene set enrichment analysis:A knowledge-based approach for interpreting genome-wide expression profiles, Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 15545-15550.
|
[19] |
. T. Wu, E. Hu, S. Xu, et al., clusterProfiler 4.0:A universal enrichment tool for interpreting omics data, Innov. 2 (2021), 100141.
|
[20] |
. M. Kanehisa, M. Furumichi, Y. Sato, et al., KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51 (2023) D587-D592.
|
[21] |
. A.P. Patel, I. Tirosh, J.J. Trombetta, et al., Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma, Science 344 (2014) 1396-1401.
|
[22] |
. R. Gao, S. Bai, Y.C. Henderson, et al., Delineating copy number and clonal substructure in human tumors from single-cell transcriptomes, Nat. Biotechnol. 39 (2021) 599-608.
|
[23] |
. J. Cao, M. Spielmann, X. Qiu, et al., The single-cell transcriptional landscape of mammalian organogenesis, Nature 566 (2019) 496-502.
|
[24] |
. K. Yoshihara, M. Shahmoradgoli, E. Martínez, et al., Inferring tumour purity and stromal and immune cell admixture from expression data, Nat. Commun. 4 (2013), 2612.
|
[25] |
. S. Morabito, F. Reese, N. Rahimzadeh, et al., hdWGCNA identifies co-expression networks in highdimensional transcriptomics data, Cell Rep. Meth. 3 (2023), 100498.
|
[26] |
. L. Garcia-Alonso, V. Lorenzi, C.I. Mazzeo, et al., Single-cell roadmap of human gonadal development, Nature 607 (2022) 540-547.
|
[27] |
. P. Shannon, A. Markiel, O. Ozier, et al., Cytoscape:A software environment for integrated models of biomolecular interaction networks, Genome Res. 13 (2003) 2498-2504.
|
[28] |
. B. He, Y. Xiao, H. Liang, et al., ASGARD is A single-cell guided pipeline to aid repurposing of drugs, Nat. Commun. 14 (2023), 993.
|
[29] |
. S. Detre, G. Saclani Jotti, M. Dowsett, A "quickscore" method for immunohistochemical semiquantitation:Validation for oestrogen receptor in breast carcinomas, J. Clin. Pathol. 48 (1995) 876-878.
|
[30] |
. C. Hu, T. Li, Y. Xu, et al., CellMarker 2.0:An updated database of manually curated cell markers in human/mouse and web tools based on scRNA-seq data, Nucleic Acids Res. 51 (2023) D870-D876.
|
[31] |
. W.C. Huang, J.H. Yen, Y.W. Sung, et al., Novel function of THEMIS2 in the enhancement of cancer stemness and chemoresistance by releasing PTP1B from MET, Oncogene 41 (2022) 997-1010.
|
[32] |
. V.G. LeBlanc, D.L. Trinh, S. Aslanpour, et al., Single-cell landscapes of primary glioblastomas and matched explants and cell lines show variable retention of inter- and intratumor heterogeneity, Cancer Cell 40 (2022) 379-392.e9.
|
[33] |
. S. Zheng, Y. Zou, Y. Tang, et al., Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative breast cancer, Oncoimmunology 11 (2022), 2020984.
|
[34] |
. L. Hu, L. Su, H. Cheng, et al., Single-cell RNA sequencing reveals the cellular origin and evolution of breast cancer in BRCA1 mutation carriers, Cancer Res. 81 (2021) 2600-2611.
|
[35] |
. X. Yan, Y. Xie, F. Yang, et al., Comprehensive description of the current breast cancer microenvironment advancements via single-cell analysis, J. Exp. Clin. Cancer Res. 40 (2021), 142.
|
[36] |
. M. Pecoraro, S. Marzocco, S. Franceschelli, et al., Trastuzumab and doxorubicin sequential administration increases oxidative stress and phosphorylation of connexin 43 on Ser368, Int. J. Mol. Sci.23 (2022), 6375.
|
[37] |
. S. Heublein, D. Mayr, A. Meindl, et al., Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis, J. Exp. Clin. Cancer Res. 36 (2017), 57.
|
[38] |
. M. Anurag, E.J. Jaehnig, K. Krug, et al., Proteogenomic markers of chemotherapy resistance and response in triple-negative breast cancer, Cancer Discov. 12 (2022) 2586-2605.
|
[39] |
. S. Vegunta, J.M. Kling, E. Kapoor, Androgen therapy in women, J. Women's Health 29 (2020) 57-64.
|
[40] |
. D.N. Edwards, V.M. Ngwa, A.L. Raybuck, et al., Selective glutamine metabolism inhibition in tumor cells improves antitumor T lymphocyte activity in triple-negative breast cancer, J. Clin. Invest. 131 (2021), e140100.
|
[41] |
. K.G.K. Deepak, R. Vempati, G.P. Nagaraju, et al., Tumor microenvironment:Challenges and opportunities in targeting metastasis of triple negative breast cancer, Pharmacol. Res. 153 (2020), 104683.
|
[42] |
. J.R. Whittle, F. Vaillant, E. Surgenor, et al., Dual targeting of CDK4/6 and BCL2 pathways augments tumor response in estrogen receptor-positive breast cancer, Clin. Cancer Res. 26 (2020) 4120-4134.
|
[43] |
. V.S. Periasamy, A. Riyasdeen, V. Rajendiran, et al., Induction of redox-mediated cell death in ERpositive and ER-negative breast cancer cells by a copper(II)-phenolate complex:An in vitro and in silico study, Molecules 25 (2020), 4504.
|
[44] |
. S. Taurin, H. Alkhalifa, Breast cancers, mammary stem cells, and cancer stem cells, characteristics, and hypotheses, Neoplasia 22 (2020) 663-678.
|
[45] |
. R. Vishnubalaji, N.M. Alajez, Epigenetic regulation of triple negative breast cancer (TNBC) by TGF-β signaling, Sci. Rep. 11 (2021), 15410.
|
[46] |
. W. Böcker, WHO classification of breast tumors and tumors of the female genital organs:Pathology and genetics, Verh. Dtsch Ges. Pathol. 86 (2002) 116-119.
|
[47] |
. N. Liu, X. Wang, Z. Zhu, et al., Selected ideal natural ligand against TNBC by inhibiting CDC20, using bioinformatics and molecular biology, Aging 13 (2021) 23702-23725.
|
[48] |
. Y. Liu, L. Teng, S. Fu, et al., Highly heterogeneous-related genes of triple-negative breast cancer: Potential diagnostic and prognostic biomarkers, BMC Cancer 21 (2021), 644.
|
[49] |
. J. Li, X. Gao, Z. Zhang, et al., CircCD44 plays oncogenic roles in triple-negative breast cancer by modulating the miR-502-5p/KRAS and IGF2BP2/Myc axes, Mol. Cancer 20 (2021), 138.
|
[50] |
. W. Li, T. Tanikawa, I. Kryczek, et al., Aerobic glycolysis controls myeloid-derived suppressor cells and tumor immunity via a specific CEBPB isoform in triple-negative breast cancer, Cell Metab. 28 (2018)87-103.e6.
|
[51] |
. K.W. Evans, E. Yuca, S.S. Scott, et al., Oxidative phosphorylation is a metabolic vulnerability in chemotherapy-resistant triple-negative breast cancer, Cancer Res. 81 (2021) 5572-5581.
|
[52] |
. Q. Wu, D.Y. Nie, W. Ba-Alawi, etal., PRMT inhibition induces a viral mimicry response in triplenegative breast cancer. Nat Chem Biol. 18 (2022) 821-830.
|
[53] |
. C.H. O'Flanagan, K.R. Campbell, A.W. Zhang, et al., Dissociation of solid tumor tissues with cold active protease for single-cell RNA-seq minimizes conserved collagenase-associated stress responses, Genome Biol. 20 (2019), 210.
|
[54] |
. G.K. Gray, C.M.C. Li, J.M. Rosenbluth, et al., A human breast atlas integrating single-cell proteomics and transcriptomics, Dev. Cell 57 (2022) 1400-1420.e7.
|
[55] |
. H.K. Yoon, T.H. Kim, S. Park, et al., Effect of anthracycline and taxane on the expression of programmed cell death ligand-1 and galectin-9 in triple-negative breast cancer, Pathol. Res. Pract. 214(2018) 1626-1631.
|
[56] |
. S. Saeed, J. Quintin, H.H.D. Kerstens, et al., Epigenetic programming of monocyte-to-macrophage differentiation and trained innate immunity, Science 345 (2014), 1251086.
|
[57] |
. K.K.W. To, D.C. Poon, Y. Wei, et al., Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer, Br. J. Pharmacol. 172 (2015) 4089-4106.
|
[58] |
. S. Lee, E. Kang, U. Lee, et al., Role of pelitinib in the regulation of migration and invasion of hepatocellular carcinoma cells via inhibition of Twist1, BMC Cancer 23 (2023), 703.
|
[59] |
. X. Lv, Y. Jia, J. Li, et al., The construction of a prognostic model of cervical cancer based on four immune-related LncRNAs and an exploration of the correlations between the model and oxidative stress, Front. Pharmacol. 14 (2023), 1234181.
|
[60] |
. F. Derakhshan, J.S. Reis-Filho, Pathogenesis of triple-negative breast cancer, Annu. Rev. Pathol. 17 (2022) 181-204.
|
[61] |
. S.Z. Wu, G.Al-Eryani, D.L. Roden, et al. A single-cell and spatially resolved atlas of human breast cancers. Nat Genet. 53 (2021) 1334-1347.
|
[62] |
. B. Pal, Y. Chen, F. Vaillant, et al., A single-cell RNA expression atlas of normal, preneoplastic and tumorigenic states in the human breast, EMBO J. 40 (2021), e107333.
|
[63] |
. J.A. Sparano, R.J. Gray, D.F. Makower, et al., Prospective validation of a 21-gene expression assay in breast cancer, N. Engl. J. Med. 373 (2015) 2005-2014.
|
[64] |
. A. Dongre, R.A. Weinberg, New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer, Nat. Rev. Mol. Cell Biol. 20 (2019) 69-84.
|
[65] |
. C.P. Bracken, G.J. Goodall, The many regulators of epithelial-mesenchymal transition, Nat. Rev. Mol. Cell Biol. 23 (2022) 89-90.
|
[66] |
. J. Yuan, Y. Zhang, Y. Liu, et al., Diffusion behaviors of integrins in single cells altered by epithelial to mesenchymal transition, Small 18 (2022), e2106498.
|
[67] |
. Y. Chen, S. Zhang, Q. Wang, et al., Tumor-recruited M2 macrophages promote gastric and breast cancer metastasis via M2 macrophage-secreted CHI3L1 protein, J. Hematol. Oncol. 10 (2017), 36.
|
[68] |
. A. Mantovani, F. Marchesi, A. Malesci, et al., Tumour-associated macrophages as treatment targets in oncology, Nat. Rev. Clin. Oncol. 14 (2017) 399-416.
|
[69] |
. X. Zhao, Q. Di, H. Liu, et al., MEF2C promotes M1 macrophage polarization and Th1 responses, Cell. Mol. Immunol. 19 (2022) 540-553.
|
[70] |
. X. Zhu, R. Liang, T. Lan, et al., Tumor-associated macrophage-specific CD155 contributes to M2-phenotype transition, immunosuppression, and tumor progression in colorectal cancer, J. Immunother. Cancer 10 (2022), e004219.
|
[71] |
. K.C. Wheeler, M.K. Jena, B.S. Pradhan, et al., VEGF may contribute to macrophage recruitment and M2 polarization in the decidua, PLoS One 13 (2018), e0191040.
|
[72] |
. X. Chen, A. Gao, F. Zhang, et al., ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation, Theranostics 11 (2021) 3392-3416.
|
[73] |
. D.V. Maybee, N.L. Ink, M.A.M. Ali, Novel roles of MT1-MMP and MMP-2:Beyond the extracellular milieu, Int. J. Mol. Sci. 23 (2022), 9513.
|
[74] |
. K.T. Flaherty, C. Robert, P. Hersey, et al., Improved survival with MEK inhibition in BRAF-mutated melanoma, N Engl J. Med. 367 (2012) 107-114.
|
[75] |
. M. Maio, M.S. Carlino, A.M. Joshua, et al., KEYNOTE-022:Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation, Eur. J. Cancer 160 (2022) 1-11.
|
[76] |
. T. Seo, E. Noguchi, M. Yoshida, et al., Response to dabrafenib and trametinib of a patient with metaplastic breast carcinoma harboring a BRAF V600E mutation, Case Rep. Oncol. Med. 2020 (2020), 2518383.
|
[77] |
. M.C. Schmid, C.J. Avraamides, H.C. Dippold, et al., Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3kγ, a single convergent point promoting tumor inflammation and progression, Cancer Cell 19 (2011) 715-727.
|
[78] |
. M. Li, V. Sala, M.C. De Santis, et al., Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth, Circulation 138 (2018) 696-711.
|
[79] |
. Z. Zhang, H. Li, C. Zhou, et al., Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells, J. Exp. Clin. Cancer Res. 35 (2016), 149.
|
[80] |
. M. Zhang, L. Zhang, R. Hei, et al., CDK inhibitors in cancer therapy, an overview of recent development, Am. J. Cancer Res. 11 (2021) 1913-1935.
|
[81] |
. J. Cicenas, K. Kalyan, A. Sorokinas, et al., Roscovitine in cancer and other diseases, Ann. Transl. Med. 3 (2015), 135.
|
[82] |
. S. Houzé, N.T. Hoang, O. Lozach, et al., Several human cyclin-dependent kinase inhibitors, structurally related to roscovitine, As new anti-malarial agents, Molecules 19 (2014) 15237-15257.
|